5′-Phosphonate modified oligoadenylates as potent activators of human RNase L

Lášek, Tomáš; Petrová, Magdalena; Kóšíová, Ivana; Šimák, Ondřej; Budêšínský, Miloś; Kozák, Jaroslav; Snášel, Jan; Vavřina, Zdeněk; Birkuš, Gabriel; Rosenberg, Ivan; Páv, Ondřej

doi:10.1016/j.bmc.2022.116632

Cited by 1 publication

(1 citation statement)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The method utilized the selective binding of dsRNA to a cellulose powder in ethanol containing buffer combined with fast protein liquid chromatography (FPLC) to remove up to 90% of dsRNA [328]. Another way to completely get rid of dsRNA contaminants is through solid phase synthesis of mRNA rather than IVT [394]. For instance, some researchers have synthesized RNA fragments up to ~ 70 nucleotides using the solid phase method [395].…”

Section: Purification Of Ivt-mrnamentioning

confidence: 99%

The use of RNA-based treatments in the field of cancer immunotherapy

Chehelgerdi

2023

Mol Cancer

View full text Add to dashboard Cite

Over the past several decades, mRNA vaccines have evolved from a theoretical concept to a clinical reality. These vaccines offer several advantages over traditional vaccine techniques, including their high potency, rapid development, low-cost manufacturing, and safe administration. However, until recently, concerns over the instability and inefficient distribution of mRNA in vivo have limited their utility. Fortunately, recent technological advancements have mostly resolved these concerns, resulting in the development of numerous mRNA vaccination platforms for infectious diseases and various types of cancer. These platforms have shown promising outcomes in both animal models and humans. This study highlights the potential of mRNA vaccines as a promising alternative approach to conventional vaccine techniques and cancer treatment. This review article aims to provide a thorough and detailed examination of mRNA vaccines, including their mechanisms of action and potential applications in cancer immunotherapy. Additionally, the article will analyze the current state of mRNA vaccine technology and highlight future directions for the development and implementation of this promising vaccine platform as a mainstream therapeutic option. The review will also discuss potential challenges and limitations of mRNA vaccines, such as their stability and in vivo distribution, and suggest ways to overcome these issues. By providing a comprehensive overview and critical analysis of mRNA vaccines, this review aims to contribute to the advancement of this innovative approach to cancer treatment.

show abstract

Section: Purification Of Ivt-mrnamentioning

confidence: 99%

The use of RNA-based treatments in the field of cancer immunotherapy

Chehelgerdi

2023

Mol Cancer

View full text Add to dashboard Cite

show abstract

5′-Phosphonate modified oligoadenylates as potent activators of human RNase L

Cited by 1 publication

References 46 publications

The use of RNA-based treatments in the field of cancer immunotherapy

The use of RNA-based treatments in the field of cancer immunotherapy

Contact Info

Product

Resources

About